LEXINGTON, Mass., Could 30, 2023 (GLOBE NEWSWIRE) — T2 Biosystems, Inc. (NASDAQ:TTOO), a pacesetter within the speedy detection of sepsis-causing pathogens and antibiotic resistance genes, immediately introduced the second largest sale of sepsis-driven T2Dx® Devices in Firm historical past.
T2 Biosystems’ distribution companion, Biomedica Poland, secured a multi-year contract for T2Dx Devices and sepsis check panels which can be anticipated to be deployed in chosen hospitals throughout Poland. The preliminary order contains seven T2Dx Devices, valued at greater than $450,000, with the potential for 9 further devices to be offered and deployed into an elevated variety of hospitals in Poland in the course of the second half of 2023. The preliminary time period of the contract secured by our distributor is for 3 years, with the potential to increase for a further two years.
“We’re thrilled with this order and look ahead to working intently with our distribution companion, Biomedica Poland, to ship our state-of-the-art sepsis diagnostic merchandise to hospitals throughout Poland,” acknowledged John Sperzel, Chairman and CEO of T2 Biosystems. “Our sepsis check income elevated by 67% in Central Europe in the course of the first quarter of 2023, in comparison with the prior 12 months interval, and we consider there may be huge potential to additional develop the adoption of our sepsis merchandise in Poland and all through Europe.”
Poland is the fifth most populous member state within the European Union, with over 40 million folks, and has greater than 1,200 hospitals. Primarily based on the findings of a 2020 survey of hospitals in Poland, it was concluded that, “there may be room for enchancment in sepsis and septic shock administration at its early section.” A research of extreme sepsis in ICU sufferers in Poland discovered morality charges from 46% to 54% and size of keep within the ICU starting from 8 to 13 days within the ICU. The introduction of the Firm’s T2Dx Instrument and sepsis check panels offers speedy detection of sepsis-causing pathogens and antibiotic resistance genes, in simply 3-5 hours, doubtlessly enabling clinicians to attain quicker focused antimicrobial remedy, cut back hospital size of keep and enhance affected person outcomes.
About T2 Biosystems
T2 Biosystems, a pacesetter within the speedy detection of sepsis-causing pathogens and antibiotic resistance genes, is devoted to enhancing affected person care and decreasing the price of care by serving to clinicians successfully deal with sufferers quicker than ever earlier than. T2 Biosystems’ merchandise embody the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2SARS-CoV-2™ Panel and are powered by the proprietary T2 Magnetic Resonance (T2MR®) expertise. T2 Biosystems has an lively pipeline of future merchandise, together with the T2Biothreat™ Panel, the T2Cauris™ Panel, and T2Lyme™ Panel, in addition to next-generation merchandise for the detection of bacterial and fungal pathogens and related antimicrobial resistance markers. For extra data, please go to www.t2biosystems.com.
This press launch accommodates forward-looking statements inside the that means of the Personal Securities Litigation Reform Act of 1995. All statements contained on this press launch that don’t relate to issues of historic reality needs to be thought of forward-looking statements, together with, with out limitation, statements relating to the potential for added instrument gross sales in Poland and the potential to additional develop the adoption of sepsis merchandise in Poland and all through Europe, in addition to statements that embody the phrases “count on,” “could,” “ought to,” “anticipate,” and related statements of a future or forward-looking nature. These forward-looking statements are primarily based on administration’s present expectations. These statements are neither guarantees nor ensures, however contain identified and unknown dangers, uncertainties and different vital components which will trigger precise outcomes, efficiency or achievements to be materially completely different from any future outcomes, efficiency or achievements expressed or implied by the forward-looking statements, together with, however not restricted to, (i) any incapability to (a) understand anticipated advantages from commitments, contracts or merchandise; (b) efficiently execute strategic priorities; (c) convey merchandise to market; (d) develop product utilization or adoption; (e) receive buyer testimonials; (f) precisely predict progress assumptions; (g) understand anticipated revenues; (h) incur anticipated ranges of working bills; or (i) enhance the variety of high-risk sufferers at buyer amenities; (ii) failure of early information to foretell eventual outcomes; (iii) failure to make or receive anticipated FDA filings or clearances inside anticipated time frames or in any respect; or (iv) the components mentioned underneath Merchandise 1A. “Danger Components” within the Firm’s Annual Report on Type 10-Ok for the 12 months ended December 31, 2022, filed with the U.S. Securities and Change Fee, or SEC, on March 31, 2023, and different filings the Firm makes with the SEC occasionally, together with our Quarterly Studies on Type 10-Q and Present Studies on Type 8-Ok. These and different vital components might trigger precise outcomes to vary materially from these indicated by the forward-looking statements made on this press launch. Any such forward-looking statements characterize administration’s estimates as of the date of this press launch. Whereas the Firm could elect to replace such forward-looking statements sooner or later sooner or later, except required by legislation, it disclaims any obligation to take action, even when subsequent occasions trigger its views to vary. Thus, nobody ought to assume that the Firm’s silence over time implies that precise occasions are bearing out as expressed or implied in such forward-looking statements. These forward-looking statements shouldn’t be relied upon as representing the Firm’s views as of any date subsequent to the date of this press launch.
Philip Journey Taylor, Gilmartin Group